Europe
BioArctic Doses First Parkinson's Patient in Trial of Alpha-Synuclein-Targeting Drug
Exidavnemab is a monoclonal antibody designed to eliminate aggregated clumps of the protein biomarker and slow progression of Parkinson's disease.
In a small validation set, the model was able to make accurate predictions about patient outcomes using routinely collected patient data.
Merus Nabs FDA Accelerated Approval for Bizengri in NRG1 Fusion-Positive NSCLC, Pancreatic Cancer
The approval is based on overall response rates from the Phase II eNRGy study, which enrolled advanced, previously treated NRG1 fusion-positive patients.
Reveal Genomics Studying HER2DX Test Impact on Breast Cancer Treatment Decisions
The trial done in collaboration with the Istituto Europeo di Oncologia will assess how the test influences oncologists' treatment plans for early-stage breast cancer patients.
UK's NICE Reverses Course on Immunocore's Kimmtrak for Advanced Uveal Melanoma
In recommending Kimmtrak, NICE factored in a new commercial agreement with the sponsor and changed its 2023 negative opinion.
Dec 2, 2024